Moneycontrol PRO
Open App

Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22

What adds to the Sun Pharma's investment case is the prospect for US specialty. The management hopes to achieve EBITDA break-even for a few products next fiscal

August 03, 2020 / 01:35 PM IST
Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22

Revlimid is a blockbuster blood cancer drug with sales of $12.1 billion for BMS in 2020.

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

Anubhav Sahu Moneycontrol Research Highlights - June quarter sales helped by domestic market and API performance - Improved margins may not be sustained in near term - A few specialty products to break even next fiscal - Valuation expensive; to benefit from sector wide rally India’s largest pharma company Sun Pharma (CMP: Rs 531 Market cap: Rs 127,573 crore) is seeing a technical break-out, post its June quarter results. Interestingly, a huge one-time exceptional charge has not curbed investors’ enthusiasm, while the improved margins have helped. Let’s have a closer...

  • PRO Panorama

    Moneycontrol Pro Panorama | The case for a 50-bps rate hike

    Sep 26, 2022 / 03:13 PM IST

    In today’s edition of Moneycontrol Pro Panorama: RBI's liquidity problem, Telecom draft bill needs rectification, plummeting Hang Seng raises China's concerns, India's road sector in quandary, and more

    Read Now
  • PRO Weekender

    Moneycontrol Pro Weekender | Fighting the Fed 

    Sep 3, 2022 / 10:06 AM IST

    India is bracing for the ripple effect of the frontloading of rate hikes by the US Fed. The question is, can it have the last laugh

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers